July 2020 – Proactive Investors: ReNeuron’s Michael Hunt says key focus now is to build dataset for retinal disease study
Proactive Investors : “ReNeuron Group agrees £80mln cell therapy licensing deal for China”
Proactive Investors ‘ReNeuron provides encouraging update to phase II eye disease trial’
Proactive Investors ‘ReNeuron Group’s phase IIb stroke trial kicks off with first patient treated’
Proactive Investors : “ReNeuron signs exosome collaboration deal with US biopharma”
OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Proactive Investors ‘ReNeuron focus on new clinical trials’
Proactive investors ‘Breakthrough to open up potential new revenue opportunities for Reneuron Plc’
Proactive Investors: Michael Hunt discusses very encouraging long-term stroke data
https://www.youtube.com/watch?v=7R4JluRuyKE
To view the full article click here…
Proactive Investors: ReNeuron gears up for Phase III stroke disability study
https://youtu.be/QJaKk3F-TQs
To view the full article click here…
